1 reports of this reaction
4.5% of all OCTINOXATE AND TITANIUM DIOXIDE reports
#19 most reported adverse reaction
SECRETION DISCHARGE is the #19 most commonly reported adverse reaction for OCTINOXATE AND TITANIUM DIOXIDE, manufactured by Noxell. There are 1 FDA adverse event reports linking OCTINOXATE AND TITANIUM DIOXIDE to SECRETION DISCHARGE. This represents approximately 4.5% of all 22 adverse event reports for this drug.
Patients taking OCTINOXATE AND TITANIUM DIOXIDE who experience secretion discharge should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SECRETION DISCHARGE is moderately reported among OCTINOXATE AND TITANIUM DIOXIDE users, representing a notable but not dominant share of adverse events.
In addition to secretion discharge, the following adverse reactions have been reported for OCTINOXATE AND TITANIUM DIOXIDE:
The following drugs have also been linked to secretion discharge in FDA adverse event reports:
SECRETION DISCHARGE has been reported as an adverse event in 1 FDA reports for OCTINOXATE AND TITANIUM DIOXIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
SECRETION DISCHARGE accounts for approximately 4.5% of all adverse event reports for OCTINOXATE AND TITANIUM DIOXIDE, making it a notable side effect.
If you experience secretion discharge while taking OCTINOXATE AND TITANIUM DIOXIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.